Head & neck cancer is especially common in regions having high alcohol and tobacco intake, and the most common type is squamous cell carcinoma. About 9 out of 10 head and neck cancers begin inside squamous cells. Chemotherapy drugs commonly used to treat head and neck cancers are cisplatin, carboplatin, and docetaxel. The EGFR-targeted drug, in combination with chemotherapy or radiation therapy for head and neck cancers, such as laryngeal or hypopharyngeal cancer, is a targeted therapy drug for head & neck cancer.
MARKET SCOPE
The "Head & neck cancer drugs market to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of head & neck cancer drugs market with detailed market segmentation by of product, labeling method, application. The head & neck cancer drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in head & neck cancer drugs market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- n the basis of product type, the market is segmented into PD Inhibitors, Microtubule Inhibitors, EGFR Inhibitors.
- n the basis of application, the market is segmented into Surgery, Radiation therapy, Chemotherapy, Immunotherapy.
MARKET DYNAMICS
Drivers:
- Rise in demand for combination therapy for the management of head & neck cancer.
- Growth in the number of R&D activities to develop ideal therapeutic.
- Growth in the number of cigarette smoking, alcohol & tobacco consumption.
Restraints:
- High cost of therapeutic drugs.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the head & neck cancer drugs market based on various segments. It also provides market size and forecast estimates from year 2021 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The head & neck cancer drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting head & neck cancer drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting head & neck cancer drugs market in these regions.
IMPACT OF COVID-19 ON HEAD AND NECK CANCER DRUG MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. The global impacts of the COVID-19 are already starting to be felt, and will significantly affect the head & neck cancer drugs market in 2020.Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
MARKET PLAYERS
The report covers key developments in the head & neck cancer drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from head & neck cancer drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for head & neck cancer drugs market in the global market. Below mentioned is the list of few companies engaged in the head & neck cancer drugs market.
The report also includes the profiles of key players in head & neck cancer drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
- Fresenius Medical Care AG and Co. KGaA
- Merck and Co., Inc.
- Pfizer Inc.
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Limited